BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25785590)

  • 21. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-34a deficiency accelerates medulloblastoma formation in vivo.
    Thor T; Künkele A; Pajtler KW; Wefers AK; Stephan H; Mestdagh P; Heukamp L; Hartmann W; Vandesompele J; Sadowski N; Becker L; Garrett L; Hölter SM; Horsch M; Calzada-Wack J; Klein-Rodewald T; Racz I; Zimmer A; Beckers J; Neff F; Klopstock T; De Antonellis P; Zollo M; Wurst W; Fuchs H; Gailus-Durner V; Schüller U; de Angelis MH; Eggert A; Schramm A; Schulte JH
    Int J Cancer; 2015 May; 136(10):2293-303. PubMed ID: 25348795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
    Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
    Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
    Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
    Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.
    Chen KH; Hsu CC; Song WS; Huang CS; Tsai CC; Kuo CD; Hsu HS; Tsai TH; Tsai CY; Woung LC; Chiou SH; Lu KH; Chen YW
    Childs Nerv Syst; 2010 Nov; 26(11):1605-12. PubMed ID: 20526717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
    Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
    Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bmi1 overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation.
    Behesti H; Bhagat H; Dubuc AM; Taylor MD; Marino S
    Dis Model Mech; 2013 Jan; 6(1):49-63. PubMed ID: 23065639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 Mutation, MYCN Amplification, and Large Cell/Anaplastic Histology in Medulloblastoma.
    Das A; Zameer L; Vinarkar S; Singh M; Parihar M; Arora N; Chandra A; Achari RB
    Indian J Pediatr; 2018 Aug; 85(8):684-685. PubMed ID: 29139064
    [No Abstract]   [Full Text] [Related]  

  • 32. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells.
    Yang MY; Lee HT; Chen CM; Shen CC; Ma HI
    Int J Mol Sci; 2014 Jun; 15(6):11013-29. PubMed ID: 24945311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma.
    Venkataraman S; Birks DK; Balakrishnan I; Alimova I; Harris PS; Patel PR; Handler MH; Dubuc A; Taylor MD; Foreman NK; Vibhakar R
    J Biol Chem; 2013 Jan; 288(3):1918-28. PubMed ID: 23212916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.
    Cormerais Y; Pagnuzzi-Boncompagni M; Schrötter S; Giuliano S; Tambutté E; Endou H; Wempe MF; Pagès G; Pouysségur J; Picco V
    J Cell Mol Med; 2019 Apr; 23(4):2711-2718. PubMed ID: 30784173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
    Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
    Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties.
    Cordeiro BM; Oliveira ID; Alves MT; Saba-Silva N; Capellano AM; Cavalheiro S; Dastoli P; Toledo SR
    Childs Nerv Syst; 2014 Jul; 30(7):1165-72. PubMed ID: 24695855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
    Levesley J; Steele L; Brüning-Richardson A; Davison A; Zhou J; Ding C; Lawler S; Short SC
    Neuro Oncol; 2018 Jan; 20(2):203-214. PubMed ID: 29016820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.